Mice Lacking NMDA Receptors in Parvalbumin Neurons Display Normal Depression-Related Behavior and Response to Antidepressant Action of NMDAR Antagonists
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
The underlying circuit imbalance in major depression remains unknown and current therapies remain inadequate for a large group of patients. Discovery of the rapid antidepressant effects of ketamine--an NMDA receptor (NMDAR) antagonist--has linked the glutamatergic system to depression. Interestingly, dysfunction in the inhibitory GABAergic system has also been proposed to underlie depression and deficits linked to GABAergic neurons have been found with human imaging and in post-mortem material from depressed patients. Parvalbumin-expressing (PV) GABAergic interneurons regulate local circuit function through perisomatic inhibition and their activity is NMDAR-dependent, providing a possible link between NMDAR and the inhibitory system in the antidepressant effect of ketamine. We have therefore investigated the role of the NMDAR-dependent activity of PV interneurons for the development of depression-like behavior as well as for the response to rapid antidepressant effects of NMDAR antagonists. We used mutant mice lacking NMDA neurotransmission specifically in PV neurons (PV-Cre+/NR1f/f) and analyzed depression-like behavior and anhedonia. To study the acute and sustained effects of a single NMDAR antagonist administration, we established a behavioral paradigm of repeated exposure to forced swimming test (FST). We did not observe altered behavioral responses in the repeated FST or in a sucrose preference test in mutant mice. In addition, the behavioral response to administration of NMDAR antagonists was not significantly altered in mutant PV-Cre+/NR1f/f mice. Our results show that NMDA-dependent neurotransmission in PV neurons is not necessary to regulate depression-like behaviors, and in addition that NMDARs on PV neurons are not a direct target for the NMDAR-induced antidepressant effects of ketamine and MK801.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“ketamine did not alter immobility or swimming during the forced swim test 30 minutes, 24 hours, or one-week post-treatment in PVCreGluN1 mice relative to GluN1f/f mice which suggests that the antidepressant-like effects of ketamine require GluN1 in PV interneurons.”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Pozzi et al., 2014
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“saline treated PVCreGluN1 and GluN1f/f mice appear to have a 2- to 3-fold higher immobility and lower swimming time relative to C57BL/6N WT which suggests that the GluN1f/f mutation was alone sufficient to impact the FST.”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Pozzi et al., 2014
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“ketamine (3 mg/kg) reduced immobility and increased swimming behavior in wild-type (WT) mice 30 minutes and 24 hours post-treatment.”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Pozzi et al., 2014
The cited source says what the claim attributes to it.
In the citing paper
“Specifically, loss of the GluN1 subunit of the NMDA receptors on parvalbumin expressing GABAergic interneurons did not alter the behavioral response to ketamine, suggesting that NMDA receptors on parvalbumin containing interneurons are not the target for ketamine's antidepressant effects (Pozzi et al., 2014).”
From BDNF - a key transducer of antidepressant effects (2016) · cites this paper as Pozzi et al., 2014
In the citing paper
“In addition, mice lacking NMDAR (GluN1) in parvalbumin-expressing interneurons, designed to mimic disinhibition of pyramidal cell activity, retained ketamine-induced antidepressant activity 57.”
From Mechanisms of ketamine action as an antidepressant (2018) · cites this paper as [57]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Depression: a new animal model sensitive to antidepressant treatments
PORSOLT, R. D., LE PICHON, M., & JALFRE, M. (1977) · Nature · doi:10.1038/266730a0 · Cited by 4,451 · cited 1×
“forced swimming test, FST) to score the antidepressant-like effects [37] of the non-competitive glutamate NMDAR antagonists ketamine and MK801 using doses and routes of administration of ketamine and MK801 previously”
MethodTrivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 1×
“It is now well recognized that in addition to ketamine and MK801 [4], [9], [12,13] various NMDAR antagonists such as amantadine and memantine can exhibit antidepressant activity in patients and in a range of preclinical screening procedures (reviewed in [14]).”
BackgroundA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766 · cited 1×
“It is now well recognized that in addition to ketamine and MK801 [4], [9], [12,13] various NMDAR antagonists such as amantadine and memantine can exhibit antidepressant activity in patients and in a range of preclinical screening procedures (reviewed in [14]).”
BackgroundParvalbumin neurons and gamma rhythms enhance cortical circuit performance
Sohal, V. S., Zhang, F., Yizhar, O., & Deisseroth, K. (2009) · Nature · doi:10.1038/nature07991 · Cited by 2,606 · cited 1×
“Of the inhibitory neurons, fast-spiking interneurons expressing the calcium binding protein parvalbumin (PV) have drawn particular interest, with several studies demonstrating their importance in fundamental cortical processes including generation of gamma oscillations [25,26].”
BackgroundDriving fast-spiking cells induces gamma rhythm and controls sensory responses
Cardin, J. A., Carlén, M., Meletis, K., Knoblich, U., Zhang, F., Deisseroth, K., Tsai, L.-H., & Moore, C. I. (2009) · Nature · doi:10.1038/nature08002 · Cited by 2,603 · cited 1×
“The behavioral relevance of the GABAergic system has also been demonstrated, both with pharmacological (reviewed in [21]) and genetic means [22,23] as well as lately with optogenetic tools [24].”
BackgroundSelf-citationNeocortical excitation/inhibition balance in information processing and social dysfunction
Yizhar, O., Fenno, L. E., Prigge, M., Schneider, F., Davidson, T. J., O’Shea, D. J., Sohal, V. S., Goshen, I., Finkelstein, J., Paz, J. T., et al. (2011) · Nature · doi:10.1038/nature10360 · Cited by 2,454 · cited 1×
“Gamma oscillations are tightly linked to cognitive functions [27] and perturbation of PV inhibition disrupts gamma oscillations and impairs cognitive functions [28–30].”
BackgroundNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 2×
“In rodents, antidepressant-like effects after acute NMDA receptor (NMDAR) antagonist treatment have been observed in many models of depression, including inescapable stress, the forced swimming test, the tail suspension test, learned helplessness models of depression, and exposure to chronic mild stress procedures [3]…”
BackgroundWillner, P. (1997) · Psychopharmacology · doi:10.1007/s002130050456 · Cited by 1,832 · cited 1×
“Chronic exposure to mild unpredictable stress has been found to reduce the consumption of, and preference for, highly palatable sucrose solution in rodents, a behavior that is reversed by antidepressants [45,46].”
BackgroundMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793 · cited 1×
“In accordance with this theory, acute ketamine administration rapidly increases glutamatergic neurotransmission in the prefrontal cortex of rodents, a process most likely mediated by presynaptic NMDA autoreceptors and/or NMDAR expressed on GABAergic interneurons [40], which are known to shape circuit function by chang…”
Background
Cited by
Mechanisms of ketamine action as an antidepressant
Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.255 · Cited by 1,127
BDNF - a key transducer of antidepressant effects
Björkholm, C., & Monteggia, L. M. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.10.034 · Cited by 958
“Specifically, loss of the GluN1 subunit of the NMDA receptors on parvalbumin expressing GABAergic interneurons did not alter the behavioral response to ketamine, suggesting that NMDA receptors on parvalbumin containing interneurons are not the target for ketamine's antidepressant effects (Pozzi et al., 2014).”
BackgroundBrain-Derived Neurotrophic Factor Signaling in Depression and Antidepressant Action
Castrén, E., & Monteggia, L. M. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.05.008 · Cited by 540
GABA interneurons are the cellular trigger for ketamine's rapid antidepressant actions
Gerhard, D. M., Pothula, S., Liu, R.-J., Wu, M., Li, X.-Y., Girgenti, M. J., Taylor, S. R., Duman, C. H., Delpire, E., Picciotto, M., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci130808 · Cited by 345
“To match the style of Camk2a and GAD67 images, Sst+ and deletion of Grin1 from PvalbCre+ mice did not block the effects of ketamine (44).”
BackgroundAn excitatory synapse hypothesis of depression
Thompson, S. M., Kallarackal, A. J., Kvarta, M. D., Van Dyke, A. M., LeGates, T. A., & Cai, X. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2015.03.003 · Cited by 265
Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs
Dale, E., Bang-Andersen, B., & Sánchez, C. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.03.011 · Cited by 234
“However, ketamine has also been shown to produce antidepressant-like behavioral responses in mice lacking NMDA receptors in parval-bumin positive interneurons [127].”
BackgroundWidman, A. J., & McMahon, L. L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718883115 · Cited by 204
Miller, O. H., Moran, J. T., & Hall, B. J. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.07.028 · Cited by 200
Franceschelli, A., Sens, J., Herchick, S., Thelen, C., & Pitychoutis, P. M. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.01.008 · Cited by 198
“In the CMS experiment, mice were subjected to the FST twice, based on the recent observation that C57BL/6 mice display stable behavior upon repeated FST exposure (Pozzi et al., 2014).”
Pham, T. H., & Gardier, A. M. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.017 · Cited by 186
“The mutation itself did not provoke a depression-like behavior, and ketamine still produced an antidepressant-like effect in the FST of mutant PV-Cre+/NR1f/f mice (Pozzi et al., 2014).”
BackgroundMechanisms of ketamine and its metabolites as antidepressants
Hess, E. M., Riggs, L. M., Michaelides, M., & Gould, T. D. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114892 · Cited by 175
New targets for rapid antidepressant action
Machado-Vieira, R., Henter, I. D., & Zarate Jr., C. A. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.12.001 · Cited by 154
Neurobiology of rapid-acting antidepressants: convergent effects on GluA1-synaptic function
Duman, R. S., Shinohara, R., Fogaça, M. V., & Hare, B. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0400-x · Cited by 154
Antidepressant actions of ketamine: from molecular mechanisms to clinical practice
Monteggia, L. M., & Zarate, C. (2015) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2014.12.004 · Cited by 149
Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants
Gould, T. D., Zarate, C. A., & Thompson, S. M. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052811 · Cited by 133
Bygrave, A. M., Masiulis, S., Nicholson, E., Berkemann, M., Barkus, C., Sprengel, R., Harrison, P. J., Kullmann, D. M., Bannerman, D. M., & Kätzel, D. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.44 · Cited by 109
Kokkinou, M., Irvine, E. E., Bonsall, D. R., Natesan, S., Wells, L. A., Smith, M., Glegola, J. A., Paul, E. J., Tossell, K., Veronese, M., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0740-6 · Cited by 116
“Evidence suggests that ketamine’s antidepressant effects could be independent from NMDA receptors expressed in PV interneurons [87] and that deletion of dopamine D2 receptors from PV interneurons induces hyperlocomotion [88].”
BackgroundNg, L. H. L., Huang, Y., Han, L., Chang, R. C.-C., Chan, Y. S., & Lai, C. S. W. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0321-5 · Cited by 82
Picard, N., Takesian, A. E., Fagiolini, M., & Hensch, T. K. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0341-9 · Cited by 71
Synaptic Regulation of a Thalamocortical Circuit Controls Depression-Related Behavior
Miller, O. H., Bruns, A., Ben Ammar, I., Mueggler, T., & Hall, B. J. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.002 · Cited by 70
“Antagonism of GluN2B- Cell R This is an open access article under the CC BY-N containing NMDARs on forebrain pyramidal neurons is sufficient and necessary for ketamine’s antidepressant actions (Kiselycznyk et al., 2015; Miller et al., 2014; Pozzi et al., 2014; Preskorn et al., 2008).”
BackgroundRapid Acting Antidepressants in Chronic Stress Models: Molecular and Cellular Mechanisms
Hare, B. D., Ghosal, S., & Duman, R. S. (2017) · Chronic Stress · doi:10.1177/2470547017697317 · Cited by 67
Rodent ketamine depression-related research: Finding patterns in a literature of variability
Polis, A. J., Fitzgerald, P. J., Hale, P. J., & Watson, B. O. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112153 · Cited by 67
Kiselycznyk, C., Jury, N. J., Halladay, L. R., Nakazawa, K., Mishina, M., Sprengel, R., Grant, S. G. N., Svenningsson, P., & Holmes, A. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.03.023 · Cited by 56
“Palachick B, Chen YC, Enoch AJ, Karlsson RM, Mishina M, Holmes A. Role of major NMDA or AMPA receptor subunits in MK-801 potentiation of ethanol intoxication.”
BackgroundResultInfluentialNogo, D., Jasrai, A. K., Kim, H., Nasri, F., Ceban, F., Lui, L. M. W., Rosenblat, J. D., Vinberg, M., Ho, R., & McIntyre, R. S. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06105-9 · Cited by 54
“2016); (ii) anticipatory reward deficits—ICSS, TEPS, BDI, SPT, SIT, ICSS (Rizvi et al.”
InfluentialWorkman, E. R., Haddick, P. C. G., Bush, K., Dilly, G. A., Niere, F., Zemelman, B. V., & Raab-Graham, K. F. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.165 · Cited by 54
Jukić, M. M., Opel, N., Ström, J., Carrillo‐Roa, T., Miksys, S. L., Novalen, M., Renblom, A., Sim, S. C., Peñas‐Lledó, E., Courtet, P., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.204 · Cited by 57
Fuxe, K., & Borroto-Escuela, D. O. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1074175 · Cited by 43
“It should be noted, however, that the antidepressant actions of ketamine remain after deletion of the obligatory NMDA NR1 subunit in parvalbumin positive GABA interneurons [48].”
BackgroundEngaging homeostatic plasticity to treat depression
Workman, E. R., Niere, F., & Raab‐Graham, K. F. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.225 · Cited by 47
Wesseling, H., Guest, P. C., Lee, C., Wong, E. H. F., Rahmoune, H., & Bahn, S. (2014) · Molecular Autism · doi:10.1186/2040-2392-5-38 · Cited by 46
“NMDAR NR1 subunit knockout in parvalbuminpositive interneurons resulted in an ASD-like phenotype [13] with impaired self-care and sociability [14] in the absence of depression-related behaviours [15].”
BackgroundKetamine: The final frontier or another depressing end?
Sial, O. K., Parise, E. M., Parise, L. F., Gnecco, T., & Bolaños‐Guzmán, C. A. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112508 · Cited by 45
“However, a different study has shown that ketamine can retain its antidepressant efficacy in systems with a NMDAR knockout in a subset of GABAergic interneurons [114].”
BackgroundAntidepressant-like effects of ketamine in a mouse model of serotonergic dysfunction
Wilson, C., Li, S., Hannan, A. J., & Renoir, T. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.107998 · Cited by 36
Scotton, E., Antqueviezc, B., Vasconcelos, M., Dalpiaz, G., Géa, L. P., Goularte, J. F., Colombo, R., & Rosa, A. R. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.114963 · Cited by 40
Ju, P., & Cui, D. (2016) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv135 · Cited by 34
“Mice with NR1-specific deletion in GABAergic interneuron Reduction the inhibitory action in GABAergic interneuron Disruption in self-care, nest building, social short-term memory, social interactions, mating frequency; increased anxiety-like behaviors in the elevated plus maze and open-field test, impaired PPI, no sig…”
BackgroundMethodMolecular and cellular dissection of NMDA receptor subtypes as antidepressant targets
Lang, E., Mallien, A. S., Vasilescu, A.-N., Hefter, D., Luoni, A., Riva, M. A., Borgwardt, S., Sprengel, R., Lang, U. E., Gass, P., et al. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.08.012 · Cited by 33
“Mice with selective loss of the obligatory GluN1 subunit restricted to PVpositive interneurons were viable and did not show changes in emotionality (Pozzi et al., 2014).”
Bygrave, A. M., Kilonzo, K., Kullmann, D. M., Bannerman, D. M., & Kätzel, D. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00835 · Cited by 43
Alvarez, R. J., Pafundo, D. E., Zold, C. L., & Belforte, J. E. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.1897-19.2020 · Cited by 33
“Remarkably, we and others have shown that ablation of this glutamatergic receptor in PV1 interneurons during adulthood, instead of early postnatal period, does not result in a SZ-compatible phenotype (Fuchs et al., 2007; Meletis et al., 2011; Pozzi et al., 2014).”
BackgroundPotential of Glutamate-Based Drug Discovery for Next Generation Antidepressants
Chaki, S., & Fukumoto, K. (2015) · Pharmaceuticals · doi:10.3390/ph8030590 · Cited by 35
“interneurons did not exhibit any impact on depressive-like behavior as evaluated using the FST or the antidepressant effects of ketamine [28], and the antidepressant effect of a selective GluN2B antagonist was intact in knockout mice lacking GluN1 on forebrain interneurons [29].”
MethodLester, H. A., Lavis, L. D., & Dougherty, D. A. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.14121537 · Cited by 30
“Recent data have diminished the likelihood that fast-spiking parvalbumin-sensitive interneurons, the most appropriate candidate, play a role (12).”
BackgroundMichaëlsson, H., Andersson, M., Svensson, J., Karlsson, L., Ehn, J., Culley, G., Engström, A., Bergström, N., Savvidi, P., Kuhn, H., et al. (2019) · Acta Physiologica · doi:10.1111/apha.13211 · Cited by 28
“However, this is in contrast to studies showing no specific effect of ketamine on fast spiking, parvalbumin‐containing interneurons.(27,28) There are also conflicting results regarding ketamine causing a hyperglutamatergic state(29) or rather a pre‐synaptic NR2B‐dependant decrease in release probability.”
ResultA new 3-hit mouse model of schizophrenia built on genetic, early and late factors
Bouët, V., Percelay, S., Leroux, E., Diarra, B., Léger, M., Delcroix, N., Andrieux, A., Dollfus, S., Fréret, T., & Boulouard, M. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.11.043 · Cited by 31
Maternal separation as a risk factor for aggravation of neuropathic pain in later life in mice
Mizoguchi, H., Fukumoto, K., Sakamoto, G., Jin, S., Toyama, A., Wang, T., Suzumura, A., & Sato, J. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.06.015 · Cited by 24
Nie, J., Wei, X., Xu, X., Li, N., Li, Y., Zhao, Y., Guan, Y., Ge, F., & Guan, X. (2020) · The FASEB Journal · doi:10.1096/fj.202000346rr · Cited by 24
Artigas, F., Celada, P., & Bortolozzi, A. A. (2018) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.01.005 · Cited by 23
“In agreement with these observations, ketamine evoked the same behavioural responses in wild-type mice and in mice lacking NMDA receptors in parvalbumin neurons (Pozzi et al., 2014).”
ResultKetamine disrupts neuromodulatory control of glutamatergic synaptic transmission
Lür, G., Fariborzi, M., & Higley, M. J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0213721 · Cited by 21
“It has been shown numerous times [30, 31] that 2 repeats of these test do not alter the animal’s performance.”
BackgroundKawaura, K., Koike, H., Kinoshita, K., Kambe, D., Kaku, A., Karasawa, J.-I., Chaki, S., & Hikichi, H. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.09.046 · Cited by 17
Molecular Mechanism and Clinical Relevance of Ketamine as Rapid‐Acting Antidepressant
Pešić, V., Petrović, J., & Jukić, M. M. (2016) · Drug Development Research · doi:10.1002/ddr.21335 · Cited by 17
Targeting the dysfunction of glutamate receptors for the development of novel antidepressants
Xia, C., He, J., Du, L., Yan, Y., Lian, W., Xu, J., & Zhang, W. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107875 · Cited by 15
Sokolenko, E., Nithianantharajah, J., & Jones, N. C. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108103 · Cited by 13
Palhano-Fontes, F., Cavalcanti-Ribeiro, P., Gonçalves, K. T. D. C., de Almeida, V. R. N., Barbosa, D. C., Ferreira, M. A. D. A., Bolcont, R., Souza, L. C. A. M. D., dos Santos, N. C., Lopes, E. I. T. C., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.09.141 · Cited by 14
Lopes, E. I. T. C., Cavalcanti-Ribeiro, P., Palhano-Fontes, F., Gonçalves, K. T. D. C., Nunes, E. A., Lima, N. B. D. M., dos Santos, N. C., de Brito, A. J. C., de Araújo, D. B., & Coelho, N. L. G. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.06.020 · Cited by 12
Stem cell therapy: a new approach to the treatment of refractory depression
Kigawa, Y., Hashimoto, E., Ukai, W., Ishii, T., Furuse, K., Tsujino, H., Shirasaka, T., & Saito, T. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1194-2 · Cited by 13
“…PV-positive cells known to correlate with cognition and executive dysfunction in schizophrenia (Nakazawa et al. 2012) and depressive-like behavior and the antidepressant effects in depression (Pozzi et al. 2014; Zhou et al. 2012) are altered in a refractory depression rat model and NSC treatment.”
BackgroundJiang, Y., Dong, Y., & Hu, H. (2024) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2023.0225 · Cited by 16
“…[13], CP-101,606 [73] and ifenprodil [74]; as well as open-channel blockers at NMDAR PCP/Mg 2+ site, including ketamine [13,15,17,48], methoxetamine (MXE) and its analogues [49,50], MK-801 [15,51,52,61], lanicemine (AZD6765) [53], dextromethorphan (DM) [54,69–71] and memantine [64– 66 , 68].”
BackgroundBrandão, A. A. C., de Deus, D. L. S., Filho, L. A. M. D. S. D., Menezes, P. M. N., Massaranduba, A. B. R., Silva, F. S., & Ribeiro, L. A. D. A. (2023) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2023.173674 · Cited by 12
Acero-Castillo, M. C., Correia, M. B. M., Caixeta, F. V., Motta, V., Barros, M., & Maior, R. S. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110088 · Cited by 8
The interactive effects of ketamine and magnesium upon depressive-like pathology
Hayley, S. P., Razmjou, S., Litteljohn, D., Rudyk, C., Syed, S., Clarke, M., Pentz, R., & Dwyer, Z. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s111131 · Cited by 9
Zhu, Y., Qu, Y., Zhang, J., Hou, J., Fang, J., Shen, J., Xu, C. S., Huang, M., Qiao, H., & An, S.-C. (2021) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000660 · Cited by 6
“A large number of studies have shown that the NMDA receptor is involved in the pathogenesis of depression (Pozzi et al., 2014; Deutschenbaur et al., 2016; Amidfar et al., 2019; Gong et al., 2020).”
BackgroundAn automated platform for Assessing Working Memory and prefrontal circuit function
Witztum, J., Singh, A., Zhang, R., Johnson, M. M., & Liston, C. M. (2023) · Neurobiology of Stress · doi:10.1016/j.ynstr.2023.100518 · Cited by 6
“…that have suggest that chronic stress has no detectable effects on the density of PV-expressing interneurons or PV-positive dendritic material (Zadro ˙ zna et al., 2011), and PV-interneurons appear not to be involved in stress effects on depression-and anxiety-like behavior (Pozzi et al., 2014).”
Barrutieta-Arberas, I., Ortuzar, N., Vaquero-Rodríguez, A., Picó-Gallardo, M., Bengoetxea, H., Guevara, M., Gargiulo, P. A., & Lafuente, J. V. (2023) · Experimental Biology and Medicine · doi:10.1177/15353702231170007 · Cited by 6
Lv, Y., Chen, P., Kuang, L., Han, Z., Solanki, B., Zhou, W., Tao, F., Chen, R., & Yao, Y. (2020) · Brain Research · doi:10.1016/j.brainres.2020.147029 · Cited by 6
“exhibited antidepressant activity in patients and in a range of preclinical screening procedures [51].”
BackgroundLa kétamine : un neuropsychotrope au mécanisme d’action innovant
Guilloux, J., Nguyen, T. M. L., & Gardier, A. M. (2023) · Biologie Aujourd hui · doi:10.1051/jbio/2023026 · Cited by 5
Understanding in vivo modelling of depression
Bannach‐Brown, A. (2019) · ERA · Cited by 2
New Progress in the Treatment of Refractory Depression with Esticketamine
孙, 诗. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.125592 · Cited by 1
Kétamine et suicidalité : modèles animaux pour comprendre son mécanisme d’action
Nguyen, T. M. L., Jollant, F., Tritschler, L., Colle, R., Corruble, E., & Gardier, A. M. (2023) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2023.10.008 · Cited by 2
Ketaminaren eragin antidepresiboak. Ekintza mekanismo berriak farmako antidepresiboen bilaketarako
Roman, L. B., Saumell-Esnaola, M., Isasti, A., Aretxabala, X., González‐Burguera, I., de Jesús, M. L., del Caño, G. G., Sallés, J., & Barrondo, S. (2019) · EKAIA Euskal Herriko Unibertsitateko Zientzi eta Teknologi Aldizkaria · doi:10.1387/ekaia.20145 · Cited by 1
The Interactive Effects of Ketamine and Magnesium Upon Depressive-like Pathology
Razmjou, S. (2014) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2014-10484 · Cited by 1
Sokolenko, E. (2019) · Minerva Access (University of Melbourne)
Ketamine: an «atypical» antidepressant, a new effect of the old analgesic
Churyukanov, V. V., & Churyukanov, M. V. (2021) · Russian Journal of Pain · doi:10.17116/pain20211901140
Möhler, H. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735371319.793560281
Möhler, H. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732838229.793560282
Duman, R. S. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732838229.793546101
Belblidia, H., & Aroune, D. (2026) · Learning & Behavior · doi:10.3758/s13420-026-00716-4
Li, Z., Si, T., Wu, Q.-R., Zhao, J.-H., Hua, W.-Z., Zhang, Y., Yang, S., Mao, Y.-Y., Zang, W., & Cao, J. (2026) · iScience · doi:10.1016/j.isci.2026.116454
“110 Antagonists of NMDARs, such as ketamine, have been shown to produce rapid antidepressant effects.”
Metadata
- Authors
- Pozzi, L., Dorocic, I. P., Wang, X., Carlén, M., & Meletis, K.
- Affiliations
- Karolinska Institutet (SE)
- Corresponding author
- Meletis, Konstantinos
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-01-16
- Volume
- 9
- Issue
- 1
- Pages
- e83879
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3894182
- OpenAlex
- W2143999471
- Cited by
- 74
- References
- 49
- Citations by year
- 2026: 2 · 2024: 4 · 2023: 5 · 2022: 3 · 2021: 6 · 2020: 8 · 2019: 12 · 2018: 8 · 2017: 4 · 2016: 5 · 2015: 12 · 2014: 5
- FWCI
- 6.32
- Type
- journal article
- Language
- en
- Update notices
- correction (2014-02-28)
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Alliance for Research on Schizophrenia and Depression
- Karolinska Institutet
- Vetenskapsrådet
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- NMDA receptor, parvalbumin interneurons, depression-like behavior, anhedonia, ketamine, rapid antidepressant effects, NMDA receptor antagonists, MK-801, GABAergic inhibition, glutamatergic system, forced swim test, sucrose preference
- MeSH terms
- Animals, Antidepressive Agents, Major Depressive Disorder, Depressive Disorder, Major, Disease Models, Animal, Food Preferences, Humans, Interneurons, Ketamine, Male, Mice, Inbred C57BL, Mice, Transgenic, Motor Activity, Parvalbumins, Swimming, Receptors, N-Methyl-D-Aspartate, Dizocilpine Maleate, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.